AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15551720 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelaic acid 15% gel
Number of subjects: 40
Study 14728005 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel plus aspirin (loading dose of 300 mg followed by 75 mg daily)
Number of subjects: 12562
Study 14728005 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel plus aspirin
Number of subjects: 12562
Study 14728005 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel in patients undergoing PCI
Number of subjects: 12562
Study 14728005 — intervention group
Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 12562
Study 9517604 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive smoking cessation program with inhaled bronchodilator
Number of subjects: 0
Study 9517604 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive smoking cessation program with placebo
Number of subjects: 0
Study 9517604 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 8000984 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose mitoxantrone (MX)
Number of subjects: 25
Study 8000984 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 3149291 — intervention group
Group type: EXPERIMENTAL
Intervention: atenolol, 50-100 mg
Number of subjects: 156
Study 3149291 — intervention group
Group type: EXPERIMENTAL
Intervention: trichloromethiazide, 2-4 mg
Number of subjects: 156
Study 3149291 — intervention group
Group type: EXPERIMENTAL
Intervention: slow release nifedipine, 40-80 mg
Number of subjects: 156
Study 3149291 — intervention group
Group type: EXPERIMENTAL
Intervention: captopril, 37.5-75 mg
Number of subjects: 156
Study 3149291 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 156
Study 31583699 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin 2 mg
Number of subjects: 69
Study 31583699 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin 4 mg
Number of subjects: 69
Study 31583699 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin 8 mg
Number of subjects: 69
Study 31583699 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 31583699 — intervention group
Group type: COMPARATOR
Intervention: Comparison of placebo to any dose of melatonin
Number of subjects: 69
Study 31583699 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall findings
Number of subjects: 69
Study 29076530 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrative exercise (IE)
Number of subjects: 47
Study 29076530 — intervention group
Group type: COMPARATOR
Intervention: Waitlist
Number of subjects: 47
Study 26921116 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized metacognitive therapy program (MCT+)
Number of subjects: 328
Study 26921116 — intervention group
Group type: COMPARATOR
Intervention: Cognitive remediation (MyBrainTraining©)
Number of subjects: 328
Study 25657309 — intervention group
Group type: EXPERIMENTAL
Intervention: MetS without T2D
Number of subjects: 78
Study 25657309 — intervention group
Group type: EXPERIMENTAL
Intervention: MetS with T2D
Number of subjects: 78
Study 25657309 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 78
Study 23609363 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol
Number of subjects: 222
Study 23609363 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol (double-vessel and multi-vessel sub-groups)
Number of subjects: 222
Study 21962194 — intervention group
Group type: EXPERIMENTAL
Intervention: Homeopathic Sulphur (6c, 12c, 30c potency)
Number of subjects: 100
Study 21962194 — intervention group
Group type: EXPERIMENTAL
Intervention: Homeopathic Pulsatilla (6c, 12c, 30c potency)
Number of subjects: 100
Study 21962194 — intervention group
Group type: COMPARATOR
Intervention: Solvent controls (plain distilled water and water-ethanol (95%) solution)
Number of subjects: 100
Study 18923232 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza vaccine
Number of subjects: 0
Study 18923232 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine vaccine
Number of subjects: 0
Study 18923232 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiangiotensin vaccine
Number of subjects: 0
Study 18923232 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-obesity vaccine
Number of subjects: 0
Study 18923232 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine targeting heat shock proteins and oxidized low-density lipoprotein
Number of subjects: 0
Study 18923232 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine to inhibit cholesteryl ester transfer protein
Number of subjects: 0
Study 17041286 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence to antipsychotic medication
Number of subjects: 409
Study 17041286 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediating variables (symptomatic impairment, global functioning, medication side effects)
Number of subjects: 409
Study 12456382 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast 10 mg daily
Number of subjects: 22
Study 12456382 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 12456382 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone/salmeterol (FP/SM)
Number of subjects: 22
Study 12456382 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone (FP)
Number of subjects: 22
Study 11465301 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal calcitonin (Miacalcin®)
Number of subjects: 0
Study 11465301 — intervention group
Group type: COMPARATOR
Intervention: Alendronate
Number of subjects: 0
Study 11465301 — intervention group
Group type: COMPARATOR
Intervention: Etidronate
Number of subjects: 0
Study 9542560 — intervention group
Group type: EXPERIMENTAL
Intervention: Deltoid injection of scopolamine 6 micrograms/kg plus morphine 200 micrograms/kg
Number of subjects: 12
Study 9542560 — intervention group
Group type: COMPARATOR
Intervention: Gluteal injection of scopolamine 6 micrograms/kg plus morphine 200 micrograms/kg
Number of subjects: 12
Study 8168033 — intervention group
Group type: EXPERIMENTAL
Intervention: Acylaminopenicillin plus aminoglycoside (Group A)
Number of subjects: 295
Study 8168033 — intervention group
Group type: EXPERIMENTAL
Intervention: Third‐generation cephalosporin plus aminoglycoside (Group B)
Number of subjects: 295
Study 8168033 — intervention group
Group type: EXPERIMENTAL
Intervention: Double beta‐lactam combination (Group C)
Number of subjects: 295
Study 8168033 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic therapy without additional antifungal therapy
Number of subjects: 295
Study 8168033 — intervention group
Group type: EXPERIMENTAL
Intervention: Empirical amphotericin B plus 5‐fluorocytosine (given to nonresponders)
Number of subjects: 295
Study 8168033 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of rifampin
Number of subjects: 295
Study 8168033 — intervention group
Group type: EXPERIMENTAL
Intervention: Fungi in microbiologically documented infections
Number of subjects: 295
Study 8168033 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukocyte counts under study
Number of subjects: 295
Study 2462402 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfuzosin (7.5 mg or 10 mg/day)
Number of subjects: 417
Study 2462402 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 417
Study 2462402 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfuzosin
Number of subjects: 417
Study 30325791 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric phase duration of 2 seconds (C2/E2)
Number of subjects: 22
Study 30325791 — intervention group
Group type: COMPARATOR
Intervention: Eccentric phase duration of 4 seconds (C2/E4)
Number of subjects: 22
Study 30049238 — intervention group
Group type: EXPERIMENTAL
Intervention: 17-alpha hydroxyprogesterone caproate (17-OHPC)
Number of subjects: 356
Study 30276916 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Functional Circuit Training (HIFCT), n=20, 3 times/week for 6 weeks, 15-minute workouts with 20s all-out bouts and 10s breaks
Number of subjects: 33
Study 30276916 — intervention group
Group type: COMPARATOR
Intervention: Moderate Aerobic Exercise (MAE), n=13, 3 times/week for 6 weeks, 50 minutes at moderate intensity
Number of subjects: 33
Study 29851640 — intervention group
Group type: EXPERIMENTAL
Intervention: Prototype houses (bamboo, shade net, timber)
Number of subjects: 6
Study 29851640 — intervention group
Group type: COMPARATOR
Intervention: Modified reference houses
Number of subjects: 6
Study 29851640 — intervention group
Group type: COMPARATOR
Intervention: Unmodified reference houses
Number of subjects: 6
Study 29851640 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-storey prototype houses
Number of subjects: 6
Study 26012697 — intervention group
Group type: EXPERIMENTAL
Intervention: Model group (n = 16)
Number of subjects: 26
Study 26012697 — intervention group
Group type: COMPARATOR
Intervention: Validation group (n = 10)
Number of subjects: 26
Study 25456367 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine with or without oxaliplatin
Number of subjects: 8734
Study 25456367 — intervention group
Group type: COMPARATOR
Intervention: XELOX or FOLFOX
Number of subjects: 8734
Study 25456367 — intervention group
Group type: COMPARATOR
Intervention: Capecitabine-based regimens
Number of subjects: 8734
Study 22965961 — intervention group
Group type: EXPERIMENTAL
Intervention: mFOLFOX6/cediranib 20 mg
Number of subjects: 1422
Study 22965961 — intervention group
Group type: COMPARATOR
Intervention: mFOLFOX6/bevacizumab
Number of subjects: 1422
Study 19944872 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus two massages (n=126)
Number of subjects: 252
Study 19944872 — intervention group
Group type: COMPARATOR
Intervention: Usual postoperative care (n=126)
Number of subjects: 252
Study 17325505 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil (0-15 ng/ml) and inhaled sevoflurane (0-6 vol%)
Number of subjects: 24
Study 17325505 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane-remifentanil anesthetics
Number of subjects: 24
Study 15044672 — intervention group
Group type: EXPERIMENTAL
Intervention: Portion-controlled group (n = 26)
Number of subjects: 60
Study 15044672 — intervention group
Group type: COMPARATOR
Intervention: Self-selected diet group (n = 27)
Number of subjects: 60
Study 11472709 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (1,200 IU at -13 hours)
Number of subjects: 10
Study 11472709 — intervention group
Group type: EXPERIMENTAL
Intervention: L-methionine (100 mg/kg at -6 hours)
Number of subjects: 10
Study 11472709 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vehicle)
Number of subjects: 10
Study 9787721 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication + diet
Number of subjects: 25
Study 9787721 — intervention group
Group type: COMPARATOR
Intervention: Diet alone
Number of subjects: 25
Study 7664725 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose of aqueous retinyl palmitate oral solution
Number of subjects: 34
Study 7664725 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment
Number of subjects: 34
Study 7664725 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of average levels of vitamin A on day 7
Number of subjects: 34
Study 2710815 — intervention group
Group type: EXPERIMENTAL
Intervention: Helium-neon laser irradiation (3 applications of 20 seconds each)
Number of subjects: 24
Study 2710815 — intervention group
Group type: COMPARATOR
Intervention: Placebo 'stimulation'
Number of subjects: 24
Study 773392 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinidine polygalacturonate (short-acting), 4 daily doses
Number of subjects: 40
Study 773392 — intervention group
Group type: COMPARATOR
Intervention: Quinidine arabogalactan sulphate (long-acting), 2 daily doses
Number of subjects: 40
Study 30720333 — intervention group
Group type: EXPERIMENTAL
Intervention: Feeding at 32-34°C (group 2)
Number of subjects: 80
Study 30720333 — intervention group
Group type: COMPARATOR
Intervention: Feeding at 22-24°C (group 1)
Number of subjects: 80
Study 27992698 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ)
Number of subjects: 103
Study 27992698 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study 25987659 — intervention group
Group type: EXPERIMENTAL
Intervention: Azacitidine
Number of subjects: 488
Study 25987659 — intervention group
Group type: COMPARATOR
Intervention: Conventional Care Regimens (CCR)
Number of subjects: 488
Study 25987659 — intervention group
Group type: EXPERIMENTAL
Intervention: Azacitidine (censored analysis)
Number of subjects: 488
Study 25987659 — intervention group
Group type: COMPARATOR
Intervention: Conventional Care Regimens (CCR) (censored analysis)
Number of subjects: 488
Study 23993326 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG surgery
Number of subjects: 1800
Study 23993326 — intervention group
Group type: COMPARATOR
Intervention: PCI
Number of subjects: 1800
Study 21895859 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine controlled-release (CR)
Number of subjects: 416
Study 21895859 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine immediate-release (IR)
Number of subjects: 416
Study 21895859 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 416
Study 19262421 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fidelity simulation (SIM)
Number of subjects: 51
Study 19262421 — intervention group
Group type: COMPARATOR
Intervention: Standard mannequin (MAN)
Number of subjects: 51
Study 17895776 — intervention group
Group type: EXPERIMENTAL
Intervention: Right-arm injection of contrast material (80 mL, iodine concentration 300 mg/mL, 2 mL/s injection rate)
Number of subjects: 60
Study 17895776 — intervention group
Group type: COMPARATOR
Intervention: Left-arm injection of contrast material (80 mL, iodine concentration 300 mg/mL, 2 mL/s injection rate)
Number of subjects: 60
Study 14996362 — intervention group
Group type: EXPERIMENTAL
Intervention: Mosbar soap containing 20% DEET and 0.5% permethrin
Number of subjects: 127
Study 14996362 — intervention group
Group type: COMPARATOR
Intervention: Placebo lotion
Number of subjects: 127
Study 11525314 — intervention group
Group type: EXPERIMENTAL
Intervention: Ro70-0004 (5 mg)
Number of subjects: 24
Study 11525314 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 11525314 — intervention group
Group type: COMPARATOR
Intervention: Sildenafil (50 mg)
Number of subjects: 24
Study 9794849 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser therapy
Number of subjects: 20
Study 9794849 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard surgery
Number of subjects: 20
Study 9794849 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative management
Number of subjects: 20
Study 9350563 — intervention group
Group type: EXPERIMENTAL
Intervention: Triclosan-containing gel/dentifrice combination
Number of subjects: 16
Study 9350563 — intervention group
Group type: COMPARATOR
Intervention: Control gel/dentifrice combination
Number of subjects: 16
Study 1778859 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefpirome 1 or 2 g bd for 5-9 days
Number of subjects: 30
Study 7340890 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg once daily
Number of subjects: 13
Study 7340890 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol 100 mg once daily
Number of subjects: 13
Study 7340890 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg once daily
Number of subjects: 13
Study 7340890 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 200 mg once daily
Number of subjects: 13
Study 7340890 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol 200 mg once daily
Number of subjects: 13
Study 30464005 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated control (IntellO2)
Number of subjects: 30
Study 30464005 — intervention group
Group type: COMPARATOR
Intervention: Manual control
Number of subjects: 30
Study 29288184 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-surgical treatment (pressure bandages, (bed) rest and wound care)
Number of subjects: 388
Study 29288184 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment (debridement, antibiotics and implant retention (DAIR))
Number of subjects: 388
Study 29288184 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-surgical treatment followed by DAIR if persistent leakage at day 16-17
Number of subjects: 388
Study 25819697 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-based nutrient supplements (LNS)
Number of subjects: 298
Study 25819697 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 298
Study 24792311 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine block (0.25%) injected into trocar incision sites, 10 mL for incisions 8 mm or greater, 5 mL for incisions 5 mm or less.
Number of subjects: 135
Study 24792311 — intervention group
Group type: COMPARATOR
Intervention: No bupivacaine block (control group).
Number of subjects: 135
Study 20931252 — intervention group
Group type: EXPERIMENTAL
Intervention: Permaquick applied with the stiff micro‐hybrid composite Amelogen Hybrid (PMQ‐H, Ultradent)
Number of subjects: 71
Study 20931252 — intervention group
Group type: EXPERIMENTAL
Intervention: Permaquick applied with the more flexible micro‐filled Amelogen Microfill (PMQ‐M, Ultradent)
Number of subjects: 71
Study 20931252 — intervention group
Group type: COMPARATOR
Intervention: Optibond FL applied with the micro‐hybrid composite Prodigy (OFL‐P, Kerr)
Number of subjects: 71
Study 21124000 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia (TH) initiated within 6-24 hours, maintained for 48 hours at 32-33°C, followed by slow rewarming.
Number of subjects: 47
Study 21124000 — intervention group
Group type: COMPARATOR
Intervention: Normothermia (control group)
Number of subjects: 47
Study 21124000 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients aged <4 years
Number of subjects: 47
Study 21124000 — intervention group
Group type: EXPERIMENTAL
Intervention: Females
Number of subjects: 47
Study 21124000 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonaccidental TBI
Number of subjects: 47
Study 21124000 — intervention group
Group type: EXPERIMENTAL
Intervention: Global injury on CT
Number of subjects: 47
Study 21124000 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial GCS and GOS scores
Number of subjects: 47
Study 18357403 — intervention group
Group type: EXPERIMENTAL
Intervention: Action Schools! BC (AS! BC) program
Number of subjects: 410
Study 18357403 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 410
Study 16166442 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib (400 mg p.o. twice daily) plus docetaxel (75 mg/m(2) every 3 weeks)
Number of subjects: 56
Study 12738091 — intervention group
Group type: EXPERIMENTAL
Intervention: Khat chewing
Number of subjects: 10
Study 12738091 — intervention group
Group type: COMPARATOR
Intervention: Lettuce (control)
Number of subjects: 10
Study 10512407 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine colostrum
Number of subjects: 0
Study 10512407 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8940729 — intervention group
Group type: EXPERIMENTAL
Intervention: Hematopoietic growth factors (HGF) such as G-CSF and GM-CSF
Number of subjects: 16
Study 8940729 — intervention group
Group type: COMPARATOR
Intervention: No HGF supplementation
Number of subjects: 16
Study 1565246 — intervention group
Group type: EXPERIMENTAL
Intervention: EMG-assisted botulinum toxin (BOTOX) injections, N = 28
Number of subjects: 52
Study 1565246 — intervention group
Group type: COMPARATOR
Intervention: Botulinum toxin (BOTOX) injections without EMG assistance, N = 24
Number of subjects: 52
Study 3907967 — intervention group
Group type: EXPERIMENTAL
Intervention: Norethisterone oenanthate (NET OEN) 50 mg alone
Number of subjects: 364
Study 3907967 — intervention group
Group type: EXPERIMENTAL
Intervention: Norethisterone oenanthate (NET OEN) 50 mg with estradiol valerate (E2 Val.) 5 mg
Number of subjects: 364
Study 3907967 — intervention group
Group type: EXPERIMENTAL
Intervention: Norethisterone oenanthate (NET OEN) 50 mg with estradiol valerate (E2 Val.) 2.5 mg or estradiol cypionate (E2 Cyp.)
Number of subjects: 364
Study 31483461 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term Treatment for Internet and Computer Game Addiction
Number of subjects: 0
Study 31483461 — intervention group
Group type: COMPARATOR
Intervention: Wait-list Control (WLC)
Number of subjects: 0
Study 30152068 — intervention group
Group type: COMPARATOR
Intervention: Intravaginal progesterone‐releasing device (IVD) containing 0.78 g progesterone and saline (low P4 concentration)
Number of subjects: 258
Study 30152068 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal progesterone‐releasing device (IVD) containing 1.56 g progesterone (high P4 concentration)
Number of subjects: 258
Study 24810757 — intervention group
Group type: EXPERIMENTAL
Intervention: INVOS monitoring
Number of subjects: 200
Study 24810757 — intervention group
Group type: COMPARATOR
Intervention: Control group without monitoring
Number of subjects: 200
Study 24623511 — intervention group
Group type: EXPERIMENTAL
Intervention: Faster-paced sessions (intertrial interval of ∼250 ms)
Number of subjects: 7
Study 24623511 — intervention group
Group type: COMPARATOR
Intervention: Slower-paced sessions (intertrial interval of ∼1,600 ms)
Number of subjects: 7
Study 22214276 — intervention group
Group type: EXPERIMENTAL
Intervention: BDP‐HFA (100 μg twice daily)
Number of subjects: 21
Study 22214276 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 22214276 — intervention group
Group type: EXPERIMENTAL
Intervention: BDP‐HFA
Number of subjects: 21
Study 19581539 — intervention group
Group type: EXPERIMENTAL
Intervention: Temsirolimus 175 mg weekly for 3 weeks followed by 75 mg weekly
Number of subjects: 162
Study 19581539 — intervention group
Group type: EXPERIMENTAL
Intervention: Temsirolimus 175 mg weekly for 3 weeks followed by 25 mg weekly
Number of subjects: 162
Study 19581539 — intervention group
Group type: COMPARATOR
Intervention: Investigator's choice therapy
Number of subjects: 162
Study 17373594 — intervention group
Group type: EXPERIMENTAL
Intervention: Stretching program (SP) of the dominant quadriceps muscle
Number of subjects: 30
Study 17373594 — intervention group
Group type: EXPERIMENTAL
Intervention: Exhaustive eccentric exercise (ECC)
Number of subjects: 30
Study 17373594 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric exercise followed by stretching program (ECC/STR)
Number of subjects: 30
Study 15362749 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide foam (2 mg/50 mL)
Number of subjects: 38
Study 15362749 — intervention group
Group type: COMPARATOR
Intervention: Betamethasone enema (5 mg/100 mL)
Number of subjects: 38